Author(s):
Samuel S Engel
Added:
1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
Author(s):
Pam Taub,Nikolaus Marx
Added:
7 months ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical…
View more
Author(s):
Vlado Perkovic
Added:
7 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Dr Farnier is a Doctor of Medicine, a researcher and a teacher. His interests include dyslipidaemia, particularly its genetic aspects. He has conducted extensive research into type 2 diabetes and the development of new lipid-lowering drugs.
View more
Job title: Advocate for Obesity; EPCO Secretary
Susie Birney lives with a food disorder called ARFID; she understands that there is not only one cause for obesity and not one treatment which will always work. Type 2 Diabetes and other co-morbidities have been health barriers for her since her 30’s. Since 2016, Susie has been a patient representative with the ASOI and an Irish representative with ECPO. This led to the start of creating a…
View more
Author(s):
Phyo Htoo
Added:
5 months ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design…
View more
Job title: Director of Center for Clinical Metabolic Research
Prof Filip Knop isDirector of Center for Clinical Metabolic Research at the Gentofte Hospital in Copenhagen, andProfessor of Endocrinology, Department of Clinical Medicine, Faculty of Health and Medical Sciences at the University of Copenhagen, Denmark.
His research, for which he has received a number of grants and honors (e.g. named “Rising star” by the European Association for the Study of…
View more